LENZ Therapeutics, Inc.

LENZ

$5.66

-3.00%

N/A-$0.18

Healthcare

Biotechnology

NASDAQ

Active Trading

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision ...

Financial Highlights of LENZ

Profitability trend

Latest / TTM · 6 periods

Gross Margin

90.1%

Net Margin

-586.7%

P/E Ratio

-1.43x

n/a

Debt / Equity

0.00

n/a

Current Ratio

13.55

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

90.1%

Net Margin

-586.7%

P/E Ratio

-1.43x

Debt / Equity

0.00

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	100.0%	0.0%	0.0%	96.3%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	-69.9%	0.0%	0.0%	-477.5%	—
Net MarginNet income as a percentage of revenue.	0.0%	-72.1%	0.0%	0.0%	-430.3%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	-69.7%	0.0%	0.0%	-426.1%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	-69.8%	0.0%	0.0%	-427.6%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	14.62	4.91	3.63	20.36	14.23	—
Quick RatioLiquid assets divided by current liabilities.	14.62	4.91	3.63	20.36	14.23	—
Cash RatioCash and equivalents divided by current liabilities.	14.61	4.68	1.90	1.94	1.19	—
Debt / AssetsDebt as a share of total assets.	0.0%	0.5%	0.5%	0.6%	0.3%	—
Debt / EquityDebt compared with shareholder equity.	0.00	-0.01	-0.00	0.01	0.00	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	7.86x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	1.60x	0.00x	0.00x	0.01x	0.17x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.32x	0.00x	0.00x	0.06x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.55x	0.00x	0.00x	0.08x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-6.89x	-1.22x	-0.81x	-12.34x	-5.61x	—
P/B RatioPrice paid for each dollar of book value.	-34.30x	-5.10x	-1.09x	3.01x	1.62x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	8.21x	0.00x	0.00x	24.15x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-8.32x	-1.30x	-1.67x	-10.26x	-6.59x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	49.9%	0.0%	—

Upstream

The Ritedose CorporationAceclidine Hydrochloride API Manufacturer(s)UnconfirmedJAS WorldwideNovo Holdings A/SPackaging & Primary Container Suppliers

Downstream

US Patients / Eye Care Professionals (ECPs)Laboratoires ThéaLotus Pharmaceutical Co., Ltd.TWSE:1795Lunatus Healthcare FZCOEverest Medicines LimitedHKEx:1952Corxel Pharmaceuticals (formerly Ji Xing Pharmaceuticals)Marubeni CorporationTYO:8002

Proxies

Bausch + Lomb CorporationNYSE:BLCO Alcon Inc.NYSE:ALC Glaukos CorporationNYSE:GKOS Opus Genetics Inc. (f/k/a Ocuphire Pharma)NASDAQ:IRD

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

No matching stocks found

LENZ Therapeutics, Inc.

Financial Highlights of LENZ

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of LENZ

Upstream

Downstream

Proxies

Financial Highlights of LENZ

Financial highlights

Snapshot

Profitability

Liquidity & leverage

Operating efficiency

Valuation ratios

Supply Chain of LENZ

Upstream

Downstream

Proxies